Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-12-22 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
6-K Filing
Foreign Filer Report
2025-12-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is a formal notification of a share transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director gifting shares to a spouse. It follows the standard regulatory format for director dealings, including the name of the PDMR, the nature of the transaction, and the specific details required by the EU Market Abuse Regulation. This falls directly under the 'Director's Dealing' category.
2025-12-19 English
6-K Filing
Foreign Filer Report
2025-12-19 English
Subcutaneous Saphnelo approved in EU
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the European Commission's approval of 'Saphnelo' for subcutaneous self-administration. It details the clinical trial results (TULIP-SC), the medical context of the disease (SLE), and the strategic implications for the company's product portfolio. It is a standard corporate press release regarding product regulatory approval, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into specific financial reporting categories like 10-K or Earnings Release.
2025-12-16 English
Enhertu approved in US for 1L HER2+ metastatic BC
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the FDA approval of a new drug treatment (Enhertu plus pertuzumab). It details the clinical trial results (DESTINY-Breast09), the regulatory approval status, and the financial implications (milestone payments). This type of corporate announcement regarding product development and regulatory milestones is classified as a Regulatory Filing (RNS) in the context of the provided definitions, as it does not fit into specific categories like financial reports, proxy statements, or shareholder meeting materials.
2025-12-16 English
6-K Filing
Foreign Filer Report
2025-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.